JPMorgan downgrades Teva as generic treatment enterprise struggles
Teva Pharmaceutical is difficult to love because it continues to be weighed down by underperformance in some enterprise areas, JPMorgan says. Analyst Chris Schott downgraded the inventory to underweight from impartial and lowered his…